Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...

BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...

BTIG analyst Gray Powell downgraded Palo Alto Networks (PANW) to Neutral from Buy without a price target After reviewing Palo Alto’s share in ...

BTIG is growing its transition management business and hired a senior executive to help boost business. The firm has hired Daniel Howell as a director who will be based in New York. His job is simple ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

BTIG analyst Jake Fuller says that while Uber‘s (UBER) commentary on its U.S. rideshare business “felt constructive” at intra-quarter appearances, the firm’s receipt data was “more ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...